Patents Examined by Chun Dahle
  • Patent number: 9580506
    Abstract: The invention relates to a method of characterizing an antibody, which method is suitable as a potency assay for batch release of a pharmaceutical composition comprising an antibody, specifically for use when applying for marketing authorization for said pharmaceutical composition. The assay provided is a method for determining the potency of a drug product comprising an FcR binding peptide, wherein at least one mechanism of action of the FcR binding peptide of the drug product is mediated through the binding of the FcR binding peptide of the drug product to a Fc receptor, wherein said method comprises determining the binding of the FcR binding peptide of the drug product to an Fc receptor.
    Type: Grant
    Filed: July 21, 2006
    Date of Patent: February 28, 2017
    Assignee: GENMAB A/S
    Inventors: Catharina Emanuele Gerarda Havenith, Tom Vink, Patrick Van Berkel, Paul Parren
  • Patent number: 9574010
    Abstract: The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: February 21, 2017
    Assignee: Zymeworks Inc.
    Inventors: Thomas Spreter Von Kreudenstein, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Paula Irene Lario, David Kai Yuen Poon
  • Patent number: 9562109
    Abstract: The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.
    Type: Grant
    Filed: November 4, 2011
    Date of Patent: February 7, 2017
    Assignee: Zymeworks Inc.
    Inventors: Thomas Spreter Von Kreudenstein, Eric Escobar Cabrera, Surjit Bhimarao Dixit, Paula Irene Lario, David Kai Yuen Poon
  • Patent number: 9518115
    Abstract: Disclosed are humanized RFB4 antibodies or antigen-binding fragments thereof. therapy of B-cell associated diseases, such as B-cell malignancies, autoimmune disease and immune dysfunction disease. Preferably, hRFB4 comprises the light and heavy chain RFB4 CDR sequences with human antibody FR and constant region sequences, along with heavy chain framework region (FR) amino acid residues Q1, F27, V48, A49, F68, R98, T117 and light chain residues L4, S22, K39, G100, V104, and K107. More preferably, the heavy and light chain variable region sequences of hRFB4 comprise SEQ ID NO:7 and SEQ ID NO:8, respectively. In certain embodiments, trogocytosis (antigen shaving) induced by hRFB4 plays a significant role in determining antibody efficacy and disease responsiveness for treatment of B-cell diseases, such as hematopoietic cancers, immune system dysfunction and/or autoimmune disease.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: December 13, 2016
    Assignee: Immunomedics, Inc.
    Inventors: Chien-Hsing Chang, David M. Goldenberg
  • Patent number: 9505826
    Abstract: The present invention relates to antibodies, immunoglobulin constructs or immunoglobulin IgG4 fusion proteins whose in vivo half-lives are increased by the combination of (i) a modified IgG4 Fc region or FcRn binding domain thereof and (ii) a modified IgG4 hinge region sequence.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: November 29, 2016
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: David Wilson, Tetsuya Taura
  • Patent number: 9499610
    Abstract: The present disclosure relates to antibodies specific for pyroglutamated A?, as well as their use in the treatment of Alzheimer's disease and as use in diagnostic methods or as diagnostic imaging ligands Further, is provided pyroglutamated N-terminal fragments of murine or human A? to generate antibodies and for use m therapeutic purposes.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: November 22, 2016
    Assignee: H. Lundbeck A/S
    Inventors: Søren Christensen, Lone Helboe
  • Patent number: 9499632
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.
    Type: Grant
    Filed: February 20, 2013
    Date of Patent: November 22, 2016
    Assignee: E.R. Squibb & Sons, L.L.C.
    Inventors: David John King, Alison Witte, Heidi N. Leblanc, Richard Theolis, Asna Masood, Mark Yamanaka, Kyra D. Zens, Sarah R. Reed, Tim Sproul, Chetana Rao-Naik, David Passmore, Dawn M. Tanamachi, Kristopher Toy
  • Patent number: 9493560
    Abstract: Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: November 15, 2016
    Assignee: AbbVie Inc.
    Inventors: Tariq Ghayur, Junjian Liu, Peter C. Isakson
  • Patent number: 9475881
    Abstract: The present invention relates to novel Fc variants that comprise at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc receptor or ligand (e.g., Fc gamma R, C1q). Additionally, the Fc variants have altered complement dependent cytotoxicity (CDC) activity and/or antibody-dependent cell-mediated cytotoxicity (ADCC). The invention further provides methods and protocols for the application of said Fc variants, particularly for therapeutic purposes.
    Type: Grant
    Filed: January 22, 2013
    Date of Patent: October 25, 2016
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Sher Bahadur Karki, Gregory L. Moore
  • Patent number: 9453199
    Abstract: Provided are a system and methods for selectively inducing expansion of a population of T cells in the absence of exogenous growth factors, such as lymphokines, and accessory cells for research purposes. The cell based expansion system and methods permit the long-term growth of CTLs, preferably human CTLs. In addition, T cell proliferation can be induced without the need for antigen, thus providing an expanded T cell population that is polyclonal with respect to antigen reactivity. Further provided are methods for using the system and methods to screen and identify antigens related to specific diseases or conditions, tumors, autoimmune disorders, or an infectious disease or pathogen, and to identify target molecule for research purposes, or for developing a vaccine based thereon.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: September 27, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, James L. Riley, Marcela Maus, Anna Kaskel, Robert Vonderheide
  • Patent number: 9453066
    Abstract: Disclosed are: an Fc binding protein having increased stability with respect to heat, acid, and/or alkalinity compared with the wild type; a method for producing same; and a method for specifically isolating protein containing an Fc binding protein binding site using said Fc binding protein as a ligand for affinity chromatography. An Fc binding protein was obtained having increased stability with respect to heat, acid, and/or alkalinity compared with the wild-type human Fc receptor by means of substituting at least one specific amino acid residue in the extracellular domain of the wild-type human Fc receptor with another amino acid residue. The Fc binding protein is useful as a ligand for affinity chromatography for example by immobilizing in a solid phase.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: September 27, 2016
    Assignees: Sagami Chemical Research Institute, TOSOH CORPORATION
    Inventors: Kouta Hatayama, Yoshiharu Asaoka, Toru Tanaka, Teruhiko Ide
  • Patent number: 9416182
    Abstract: Bispecific antibodies are provided that specifically bind both Tumor Necrosis Factor alpha (TNF?) and Interleukin-17 (IL-17). The bispecific antibodies of the invention are useful for treating various autoimmune diseases, including Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS).
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: August 16, 2016
    Assignee: Eli Lilly and Company
    Inventors: Barrett Allan, Andrew Lawrence Glasebrook, Jirong Lu, Ying Tang, Derrick Ryan Witcher, Donmienne Doen Mun Leung, Pia Pauliina Yachi, Andrew Charles Vendel
  • Patent number: 9394366
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: July 19, 2016
    Assignee: Xencor, Inc.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Patent number: 9359448
    Abstract: Bispecific antibodies are provided that specifically bind B-cell Activating Factor of the TNF Family (BAFF) and Interleukin-17A (IL-17) and are characterized as having high affinity and strong neutralizing properties to both BAFF and IL-17. The bispecific antibodies of the invention are expected to be useful in treating Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriasis (Ps), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PA), primary Sjögren's Syndrome (pSS), or Multiple Myeloma (MM).
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: June 7, 2016
    Assignee: Eli Lilly and Company
    Inventors: Barrett Allan, Robert Jan Benschop, Jirong Lu
  • Patent number: 9353187
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: May 31, 2016
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Patent number: 9334329
    Abstract: The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: May 10, 2016
    Assignee: BioAlliance C.V.
    Inventors: Shih-Yao Lin, Leewen Lin, Yu-Ying Tsai
  • Patent number: 9328170
    Abstract: The present invention is directed to methods and compositions for the production of Fc-containing polypeptides comprising mutations at positions 243, 264, 267 and 328 of the Fc region.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: May 3, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventor: Dongxing Zha
  • Patent number: 9296815
    Abstract: Rationally designed antibodies and polypeptides that comprise multiple Fc region amino acid substitutions that synergistically provide enhanced selectivity and binding affinity to a target Fc receptor are provided. The polypeptides are mutated at multiple positions to make them more effective when incorporated in antibody therapeutics than those having wild-type Fc components.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: March 29, 2016
    Assignee: Zymeworks Inc.
    Inventors: Igor D'Angelo, Dustin Bleile, Stacey A. L. Tom-Yew, Eric Escobar-Cabrera, Paula I. Lario, Anders Ohrn, David K. Y. Poon, Surjit B. Dixit
  • Patent number: 9284589
    Abstract: Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralize eotaxin-1 activity. The antibodies VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT 213. One or more complementary determining regions (CDRs) of the CAT-212/-213 VH and/or VL domains, especially VH CRD3 in other antibody framework regions. Compositions containing specific binding members, and their use in methods of inhibiting or neutralizing eotaxin, including methods of treatment of the human or animal body by therapy.
    Type: Grant
    Filed: March 24, 2014
    Date of Patent: March 15, 2016
    Assignee: Medimmune Limited
    Inventors: Tristan John Vaughan, Alison Jane Wilton, Stephen Smith, Sarah Helen Main
  • Patent number: 9260523
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: February 16, 2016
    Assignee: Xencor, Inc.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar